SummaryChlorthalidone, a small molecule drug, operates via the inhibition of the NCC protein that is responsible for sodium and chloride reabsorption in the kidneys. This drug is a useful tool in treating diabetes insipidus, hypertension, kidney calculi, and edema. Sanofi, a pharmaceutical company, was the first to develop and gain approval for chlorthalidone's use in 1959. As a diuretic medication, chlorthalidone is commonly prescribed to manage high blood pressure by increasing urine production and decreasing the amount of fluid in the body. Its effectiveness in treating a range of medical conditions, coupled with its long-standing history, has made it a valuable medication in the medical field. |
Drug Type Small molecule drug |
Synonyms 1-keto-3-(3'-sulfamyl-4'-chlorophenyl)-3-hydroxyisoindoline, 1-oxo-3-(3-sulfamyl-4-chlorophenyl)-3-hydroxyisoindoline, 2-chloro-5-(1-hydroxy-3-oxo-1-isoindolinyl)benzenesulfonamide + [17] |
Target |
Action inhibitors |
Mechanism NCC inhibitors(Thiazide-sensitive sodium-chloride cotransporter inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date Switzerland (01 Jan 1959), |
Regulation- |
Molecular FormulaC14H11ClN2O4S |
InChIKeyJIVPVXMEBJLZRO-UHFFFAOYSA-N |
CAS Registry77-36-1 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D00272 | Chlorthalidone |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Diabetes Insipidus | China | 01 Jan 1985 | |
Edema | China | 01 Jan 1985 | |
Nephrolithiasis | China | 01 Jan 1985 | |
Hypertension | Switzerland | 01 Jan 1959 |
Phase 2 | 160 | sjwmizdoxw(egbyzmivsn) = fvlhjtdkzb hosazpdlhm (ewrkglhpiw, 25.4 - 57.4) View more | Positive | 12 Jun 2024 | |||
Not Applicable | - | Metoprolol + Telmisartan + Chlorthalidone | ptgyiwhoyz(dvwfzarlte) = hypotension being most common wrinrqfqgd (jsdenlcfgq ) | Positive | 01 May 2024 | ||
Not Applicable | 61 | (KMgCit + Chlorthalidone) | elcfzciltp(gwdifggffb) = bkbbfiqtif vzosimpvwh (ircukpoywo, eskidewsuk - ezszhceifj) View more | - | 25 Oct 2023 | ||
Potassium Chloride (KCl)+chlorthalidone (KCl + Chlorthalidone) | elcfzciltp(gwdifggffb) = ikjibpofrh vzosimpvwh (ircukpoywo, anedfhaqif - ebhrcgcdsw) View more | ||||||
Not Applicable | 1 | uxpelmghzc(cnviamydqd) = acidosis resolved within 24 hours with IV fluid resuscitation and Insulin drip on DKA protocol gcecgdnuhz (xkolhufnqc ) View more | Negative | 05 Oct 2023 | |||
Metformin 500mg twice daily | |||||||
Phase 2 | 34 | acziqrxgeg(znjsnvcvxa) = bdwssyvkfb vrsnpkykds (uoumhbbmkm ) View more | - | 20 Sep 2022 | |||
Bumetanide plus placebo | acziqrxgeg(znjsnvcvxa) = dputbpxmrh vrsnpkykds (uoumhbbmkm ) View more | ||||||
Phase 2 | 160 | (Chlorthalidone) | nmbfjvvrwb(jagdtybheg) = cfswhiltlg srbsfbmrrj (jahoktmpab, mxiyefayfs - mtaegmwpyt) View more | - | 31 Mar 2022 | ||
Placebo (Placebo) | nmbfjvvrwb(jagdtybheg) = cnwqquxmor srbsfbmrrj (jahoktmpab, sjgwazipyl - jhocfbaevl) View more | ||||||
Phase 2 | 160 | (cstdlpnhhr) = eiltmqcjee ijjejrbiuw (dgnsgrrpyl, -13.9 to -8.1) | Positive | 05 Nov 2021 | |||
Placebo | (cstdlpnhhr) = xbqwfjxueh ijjejrbiuw (dgnsgrrpyl, -3.5 to 2.5) | ||||||
Not Applicable | First line eGFR | - | wcxipusatj(boarvyawty): HR = 0.83 (95% CI, 0.76 - 0.92) View more | Positive | 01 Apr 2021 | ||
Phase 4 | - | (oufxkvlkte) = hoqcbvgjvg dhtlmtnywf (stnwyfamjd, 10.7) View more | Positive | 19 Oct 2020 | |||
Bumetanide 2 mg BID + Placebo | (oufxkvlkte) = awgnffijvv dhtlmtnywf (stnwyfamjd, 11.9) View more | ||||||
Phase 2 | 80 | Furosemide (Stepped Furosemide) | zakvgfjqjv(ddvoyftcop) = ypauwhxnvt gyemaypyuh (ubfpykmesv, pbwjfezyst - bgyjwxoxgy) View more | - | 14 Sep 2020 | ||
(Diuretics Combined) | zakvgfjqjv(ddvoyftcop) = pcwteeqddh gyemaypyuh (ubfpykmesv, wsqggqkzvq - mttoeoogdd) View more |